P2L-003

Overview

P2L-003 is a selective PAR2 antagonist with an IC 50 of 0.62 μM in HT-29 cells. P2L-003 blocks PAR2 -mediated Ca 2+ mobilization without affecting PAR1 , PAR4 , or ATP -mediated signaling and dose-dependently suppresses the downstream MAPK signaling cascades, including ERK1/2 and p38 phosphorylation. P2L-003 can be used for colon cancer research.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Protease Activated Receptor (PAR) | Products > Signaling Pathways > p38 MAPK

Product Information

• Catalog No.: HY-180244
• CAS No.: 1359416-20-8
• Molecular Formula: C23H25ClN4O3S
• Molecular Weight: 472.99
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source